A company that claims to have the first drug to slow mental decline from Alzheimer’s disease made its case to scientists Thursday but left them sharply divided over whether there’s enough evidence of effectiveness for the medicine to warrant federal approval.
Excitement and skepticism have surrounded aducanumab since its developers stopped two studies…
The complete workflow is depicted in Fig. 1. To investigate the association between NPIs and AD, we initially conducted preprocessing and integration of biomedical triples...
Compared with other neurologic problems, few films have been dedicated to degenerative dementia. To our knowledge, this is the first systematic review about the...